


'Papilocare' (Procare Health) shows evidence of efficacy at restoring HPV-induced lesions

MADRID, 19 (EUROPA PRESS)

A clinical trial has shown evidence of the efficacy of 'Papilocare' vaginal gel in restoring cervix lesions after 6 months of treatment among 88 percent of patients infected by high risk HPV, which is mainly responsible for developing cervical cancer. Additionally, it completely eliminates the virus in 63 percent of patients, according to these results.



HPV infection is the most common sexually transmitted disease, given that around 80 percent of people in the world, both men and women, will become infected at some point in their life. It is a virus that is normally cleared naturally by the patient's own immune system. However, 42 percent of low-grade lesions do not clear up unaided among women infected with high risk HPV after 2 years.

Despite being a temporary infection, with most patients eliminating it unaided, and the effective vaccination programmes for preventing the infection, HPV still causes 2,500 cases of cervical cancer in Spain every year, being the fourth cause of death among women aged 15-44 years old in Spain.

The company behind 'Papilocare', Procure Health, launched the product in 2016. Since then, they have carried out the 'Paloma' randomised, multicentre clinical trial, controlled with regular clinical practice. The aim is to evaluate its efficacy at restoring low grade HPV-induced cervix lesions.

Ending in June 2019, the trial recruited 101 patients and provided evidence for restoring low grade cervix lesions among 85 percent of treated patients at 6 months. This result was even more significant among women infected with high risk HPV, which is mainly responsible for cervical cancer, restoring lesions

among 88 percent of patients.

Additionally, it has shown evidence of an increase of 57 percent in high risk virus clearance, with 63 percent elimination occurring among patients treated for 6 months compared to 40 percent for the control group. Furthermore, this result is very consistent with the 3 results presented by independent studies carried out by public teaching hospitals in Spain, who report an efficacy for 'Papilocare' of 50 to 70 percent when clearing high risk HPV.